Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
FDA Approvals
FDA Approvals
FDA Approved Fyarro for Malignant Perivascular Epithelioid-Cell Tumor
Read More
FDA Approvals
Oral Scemblix FDA Approved for Patients with Ph-Positive Chronic Myeloid Leukemia
Read More
FDA Approvals
Verzenio with Endocrine Therapy FDA Approved for Adjuvant Treatment of Early Breast Cancer
Read More
FDA Approvals
Tecartus FDA Approved for Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Read More
FDA Approvals
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
Read More
FDA Approvals
Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma
Read More
FDA Approvals
Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors
Read More
FDA Approvals
Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
Read More
FDA Approvals
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Read More
FDA Approvals
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
Read More
4
5
6
7
8
9
10
Page 7 of 18
Results 61 - 70 of 180